The use of slower-acting (Class III) symptom-modifying antirheumatic drugs in rheumatoid arthritis

Clinical Immunotherapeutics

Volumn 5, Issue 4, 1996, Pages 309-325

  Wilke, William S ^a   Cash, Joseph M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029870271     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259329     Document Type: Review

References (141)

1. Edmonds JP, Scott DL, Fürst DE, et al, New classification of antirheumatic drugs: the evolution of a concept, J Rheumatol 1993; 20: 585-7
2. Cash JM, Klippel JH, Second-line drug therapy for rheumatoid arthritis, N Engl J Med 1994; 330: 1368-75
3. Gubner R, August S, Ginsberg V, Therapeutic suppression of tissue reactivity: II, Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sei 1951; 221: 176-82
4. Salach R, Cash JM, Methotrexate: the emerging drug of choice for serious rheumatoid arthritis, Clin Ther 1994; 16: 912-22
5. Thompson RN, Watts C, Edelman J, et al, A controlled two centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760-3
6. Weinblatt ME, Coblyn JS, Fox DA, et al, Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985 ; 312: 818-22
7. Williams HJ, Willkens RF, Samuelson CO, et al, Comparison of low dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721-30
8. Anderson PA, West SG, O'Dell JR, et al, Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunological effects in a randomized double blind study. Ann Intern Med 1985; 103:489-96
9. Kremer JM, Lee JK, A long term prospective study of the use of methotrexate in rheumatoid arthritis: update after a mean of 53 months. Arthritis Rheum 1988; 31: 577-84
10. Weinblatt ME, Trentham DE, Fraser PA, et al, Long term prospective trial of low dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167-75
11. Wan SH, Huffman DH, Azarnoff DL, et al, Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974; 34: 3487-91
12. Rheumatoid Arthritis Clinical Trial Archive Group, The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218-23
13. RA Clinical Trial Archive group, The effect of age and renal function on the efficacy and toxicity of MTX in RA. J Rheumatol 1995:22:218-3
14. Ahern M, Booth J, Loxton A, et al, Methotrexate kinetics in rheumatoid arthritis: is there an interaction with NSAIDs? J Rheumatol 1988; 15: 1356-60
15. Daly H, Boyle R, Roberts C, et al, Interaction between methotrexate and nonsteroidal anti-inflammatory drugs. Lancet 1986; I: 559
16. Cronstein BN, Molecular mechanism of methotrexate action in inflammation. Inflammation 1992; 16: 411-23
17. Kremer JM, The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994; 21: 1-5
18. Fürst DE, Erikson N, Clute L, et al, Adverse experience with methotrexate during 176 weeks of a longterm prosepctive trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1628-35
19. MacKinnon SK, Starkebaum G, Wilkens RF, Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985; 15: 119-26
20. Cash JM, Wilke WS, Guidelines for routine liver biopsy during methotrexate treatment. Cleve Clin J Med 1994; 61:317-8
21. Kremer JM, Alarcon GS, Lightfoot RW, et al, Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28
22. Carson CW, Cannon GW, Egger MJ. et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose methotrexate. Semin Arthritis Rheum 1987; 16: 186-95
23. Cash JM, Does methotrexate cause pulmonary fibrosis? J Musculoskeletal Med 1994; 11:11-2
24. Rustin GJS, Rustin F, Dent J, et al, No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med 1982; 308: 473-6
25. Bailin PL, Tindall JP, Roenigk HH, et al. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospectiveprospective analysis. JAMA 1975; 232: 359-62
26. Tailan B, Gamier G, Caslanet J, et al, Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate. Clin Rheumatol 1993; 12:93-4
27. Shiroky JB, Frost A, Skelton JD, et al, Complications of immunosuppression associated with weekly low dose MTX. J Rheumatol 1991; 18: 1172-5
28. Kamel OW, van de Rijn M, Weiss LM, et al, Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317-21
29. Levy J, Barnett EV, MacDonald NS, et al, Effects of AZA on gammaglobulin synthesis in man. J Clin Invest 1972; 51: 2233-8
30. Abom B, Pedersen BK, The in vivo effect of triethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on natural killer cell activity of patients with rheumatoid arthritis. Clin Exp Rheumatol 1987; 5: 47-52
31. Urowitz MB, Gordon DA, Smythe HA, et al, Azathioprine in rheumatoid arthritis: a double-blind, cross-over study. Arthritis Rheum 1973; 16 (3): 411-8
32. DeSilva M, Hazleman BL, Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981 ; 40: 560-3
33. Cash JM, Klippel JH, Rheumatic disease and cancer. Clin Exp Rheumatol 1991; 9: 109-2
34. Kinlen LJ, Sheil AGR, Peto J, et al, Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979; 2: 1461-6
35. Silman AJ, Pétrie J, Hazleman B, et al, Lymphoproliferative cancer and other malignancy in patients with rheumatoid ar-thritis treated with azathioprine: a 20 year follow-up study. Ann Rheum Dis 1988; 47: 988-2
36. PullarT, Hunter JA, Capell HA, Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ 1983; 287: 1102-4
37. van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al, Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8
38. Neumann VC, Taggart AJ, Legallez P, et al, A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol 1986; 13: 285-7
39. Amos RS, Pullar T, Bax DE, et al, Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. BMJ 1986:293:420-3
40. Jaffe IA, Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963:22: 71-3
41. Multicentre Trial Group, Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973; 1: 275-80
42. Dixon ASJ, Davies J, Dormandy TL, et al, Synthetic Dpenicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis 1975:34:416-21
43. Lipsky PE, Ziff M, Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4. J Clin Invest 1980; 65: 1069-76
44. Hakoda M, Taniguchi A, Kamatani N, et al, Intermittent treatment with d-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis. J Rheumatol 1994:21: 1637-41
45. Bernelot Moens HJ, Ament HJW, Feltkamp TEW, et al, Longterm follow-up of treatment with D-penicillamine for rheumatoid arthritis: effectiveness and toxicity in relation to HLA antigens. J Rheumatol 1987; 14: 1115-9
46. Hall CL, Jawad S. Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. BMJ 1988:296: 1083-6
47. Stein HB, Schroeder ML, Dillon AM. Penicillamine-induced proteinuria: risk factors. Semin Arthritis Rheum 1986; 15: 282-7
48. Delamere JP, Jobson S, MacKintosh LP. et al. Penicillamine induced myasthenia in rheumatoid arthritis: its clinical and genetic features. Ann Rheum Dis 1983; 42: 500-4
49. Cox PJ, Cyclophosphamide cystitis - identification of acrolein as the causative agent, Biochem Pharmacol 1979; 28: 2045-9
50. Clements PJ, Yu DTY, Levy J, et al. Effects of Cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis. Arthritis Rheum 1974; 17: 347-53
51. Zhu L-P, Cupps TR, Whalen G, et al, Selective effects of cyclophosphamide therapy activation, proliferation and differentiation of human B cells. J Clin Invest 1987; 79: 1082-90
52. Boumpas DT, Austin HA, Vaughn EM. et al. Risk for sustained amenorrhea in patients with systemic lupus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366
53. Scherbe! AL, Harrison JW, Atdjian M, Further observations on the use of 4-aminoquino!ine compounds in patients with rheumatoid arthritis or related diseases. Cleve Clin Q 1958; 25:29
54. Hobbs HE, Sorsby A, Freedman A, Retinopathy following chloroquine therapy. Lancet 1959; 2: 478
55. Fox RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993: 23 (2 Suppl. 1): 82-91
56. HERA Study Group, A randomized trial of hydroxychloroquine in early rheumatoid arthritis. Am J Med 1995: 98: 156-68
57. Clark P, Casas E, Tugwell P, et al, Hydroxychloroquine compared to placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993; 1067-71
58. Hamilton EBD, Scott JT, Hydroxychloroquine sulfate (Plaquenil) in treatment of rheumatoid arthritis. Arthritis Rheum 1962:5:502
59. Ellman A, Gullberg R, Nilsson E. et al. Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol 1976:5: 161
60. Easterbrook M, The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 1993; 23 (2 Suppl. 1 ): 62-7
61. Forestier J, L'aurothiopie dans les rhumatismes chroniques. Bull Mem Soc Med Hop Paris 1929; 53: 323
62. Felson DT, Anderson JJ, Meenan RF, Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum 1992:35: 1117-25
63. Rau R, Herborn G, Karger T. et al. A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12months. Semin Arthritis Rheum 1991; 21 (2 Suppl. I): 13-20
64. Wolfe F, The curious case of intramuscular gold. Rheum Dis Clin North Amer 1993; 19: 173-87
65. Epstein WV, Hencke CJ, Yelin EH, et al, Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis [see comments]. Ann Intern Med 1991; 114: 437-4
66. Silvrerg DS, Kidd EG, Shnitka TK, et al, Gold nephropathy: a clinical and pathologic study. Arthritis Rheum 1970; 13: 812-25
67. Hess A, Tutschka P, Pu Z, et al, Effect of cyclosporine A on human lymphocyte responses in vitro: IV. Production of T cell stimulatory growth factors in CS treated primary MLR cultures. J Immunol 1982; 128: 360-7
68. Handschumacher R, Harding M, Rice J, et al. Cyclophilin: a specific cytosolic binding protein for cyclosporine A. Science 1984;226:554-7
69. Colomboni P, Robb A, Hess A, Cyclosporin A binding to calmodulin: a possible site of action on T-lymphocytes. Science 1985; 228: 337
70. Dougados M, Awada H, Amor B, Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 pa tients. Ann Rheum Dis 1988; 47: 127-33
71. Forre O, Norwegian Arthritis Study Group, Radiographie evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Arthritis Rheum 1994:37: 1506-12
72. Tugwell P, Bombardiere, Gent M, et al, Low-dose Cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990:335: 1051-5
73. Yocum DE, Klippel JH, Wilder RL, et al, Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study. Ann Intern Med 1988; 109: 863-9
74. Cash JM, Wilder RL, Refractory rheumatoid arthritis: therapeutic options. Rheum Dis Clin North Amer 1995; 21: 1-18
75. Altman RD, Ferez GO, Sfakianakis ON, Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992:93:396-402
76. Sherrer YS, Bloch DA, Mitchell DM, et al. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986: 29: 494-50
77. Wolfe F, Hawley DJ, Cathey MA, Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18: 1290-7
78. Pincus T, Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037-41
79. Wilske KR, Healey LA, Remodelling the pyramid - a concept whose time has come. J Rheumatol 1989; 16: 565-7
80. Fries JF, Re-evaluating the therapeutic approach to rheumatoid arthritis: the 'saw-tooth' strategy. J Rheumatol 1990; 17: 12-5
81. Willkens RF, Prognostic staging for therapy of rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 40-3
82. Wilke WS, Clough JD, Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 1991; 21: 21-34
83. van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologie damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21: 425-9
84. Dawes PT, Fowler PD, Clarke S, et al, Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiologie progression. Br J Rheumatol 1986; 25: 44-9
85. Capell HA, Lewis D, Carey J, A 3-year follow-up of patients allocated to placebo or oral or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis 1986; 45: 705-11
86. van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, et al, Prognostic factors for radiographie damage and physical disability in rheumatoid arthritis: a prospective follow-up of 147 patients. BrJ Rheumatol 1992; 31: 519-25
87. Guillemin F, Briancon S, Pourel J, Functional disability in rheumatoid arthritis: two different models in early and established disase. J Rheumatol 1992; 19: 366-9
88. Scott DL, Dawes PT, Fowler PD, et al, Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q J Med 1985; 213: 49-59
89. Raskar JJ, Cosh JA, The natural history of rheumatoid arthritis: a 15-year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol 1984; 3: 11-20
90. Hakala M, Nieminen P, Koivisto O, More evidence from a community-based series of better outcome in rheumatoid arthritis: data on the effect of multidisciplinary care on the retention of functional ability. J Rheumatol 1994; 21: 1432-7
91. Sherrer YS, Bloch DA, Mitchell DM, et al, Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 1987; 14: 705-9
92. Suarez-Alamazor ME, Soskoline CL, Saunders D, et al, Outcome in rheumatoid arthritis: a 1985 inception cohort study. J Rheumatol 1994; 21: 1438-46
93. Wilke WS, Sweeney TJ, Calabrese LH, Early aggressive therapy for rheumatoid arthritis: concerns, descriptions and estimate of outcome. Semin Arthritis Rheum 1993; 23: 26-41
94. Wilke WS, Duna OF, When resistant RA calls for aggressive intervention. J Musculoskeletal Med 1994: June: 33-43
95. Duna GF, Calabrese LH, Wilke WS, A graduated step therapy paradigm for the treatment of rheumatoid arthritis. Arthritis Rheum 1993; 36 Suppl.: S269
96. O'Dell J, Haire C, Erikson N, et al, Triple DMARD therapy for rheumatoid arthritis is well tolerated. Arthritis Rheum 1994; 37 Suppl. 6: R10
97. Boers M, Ramsden M, Long-acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991; 18: 316-24
98. Paulus HE, Current controversies in rheumatology: the use of combinations of disease-modifying anti-rheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990; 33: 113-20
99. Pullar T, Brooks PM, Schwarzer AC, Combination therapy in rheumatoid arthritis. Br J Rheumatol 1991; 30: 311-2
100. Fowler P, Dawes PT, Sheehan TP, et al, Combination therapy in rheumatoid arthritis - study design. Br J Rheumatol 1987; 26: 314-6
101. Shiroky JB, Watts CS, Neville C, Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. Arthritis Rheum 1989; 32: 1160-4
102. Lee S, Solomon G, Treatment of rheumatoid arthritis (RA) with combination of D-penicillamine (DPCN) and methotrexate (MTX). Arthritis Rheum 1990; 33 Suppl.: R39
103. Brawer AE, The combined use of oral methotrexate and intramuscular gold in rheumatoid arthritis. Arthritis Rheum 1988; 31 Suppl.: RIO
104. Fair M, Kitas G, Bacon PA, Sulfasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate. Clin Rheumatol 1988; 7: 242-8
105. Singleton PT, Cervantes AG, Chrysotherapy and concomitant use of antimalarial drug therapy in rheumatoid arthritis. Arthritis Rheum 1982; 25 Suppl.: S115
106. McCarty DJ, Carrera GF, Intractable rheumatoid arthritis: treatment with combined cyclophosphamide, azothioprim and hydroxychloroquine. JAMA 1982; 248: 1718-23
107. Langevitz P, Kaplinsky N, Ehrenfel D, et al, Intractable RA treatment with combined methotrexate, azathioprim and hydroxychloroquine. Br J Rheumatol 1989; 28: 271-2
108. Yasuda M, Sakai K, Oribe M, Efficacy of additive DMARD therapy in patients with rheumatoid arthritis: double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate. J Rheumatol 1994; 21:44-50
109. Haagsma C, van Kiel P, de Rooij DJ, et al, Combination therapy in RA: sulfasalazine and methotrexate. Arthritis Rheum 1993; 36 Suppl.: S53
110. Kantor SM, Wallin BA, Grier CG, et al, Combination of auranofin and methotrexate as initial DMARD therapy in RA. Arthritis Rheum 1990; 33 Suppl.: S60
111. Porter DR, Capell HA, Hunter J, Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with suboptimal response to intramuscular gold therapy. J Rheumatol 1993; 20: 645-9
112. Bensen W, Tugwell P, Roberts RM, et al, Combination therapy of cyclosporin with methotrexate and gold in rheumatoid arthritis (two pilot studies). J Rheumatol 1994; 21: 2034-8
113. Tugwell P, Pincus T, Yocum D, et al, A multi-centre doubleblind, randomized trial of low-dose cyclosporin and placebo therapy in combination with methotrexate in patients with severe rheumatoid arthritis, Arthritis Rheum 1995; 37 Suppl.: S361
114. Lewis P, Hazleman B, Böigen D, et al, In: Gordon JL, Hazleman BL, editors. Rheumatoid arthritis: cellular pathology and pharmacology. Amsterdam: Elsevier-North Holland, 1977: 280
115. Rau R, Karger T, European experience. In Wilke WS, editor. Methotrexate therapy in rheumatic disease. New York (NY): Marcel Dekker, 1989:57-90
116. Williams HJ, Ward JR, Reading JC, et al, Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35: 259-69
117. Bunch TL, O'Duffy JD, Tompkins RB, et al, Controlled trial of hydroxychloroquine and D-penicillamine singly and in com-bination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984:27:267-76
118. Gibson T, Emery P, Armstrong RD, et al, Combined Dpenicillamine and chloroquine treatment of rheumatoid arthritis: a comparative study. Br J Rheumatol 1987: 26: 279-84
119. Taggart AJ, Astbury HC, Dixon JS, et al. Sulfasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. BrJ Rheumatol 1987: 26: 32-6
120. Scott DL, Dawes PT, Tunn E, et al, Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized placebo-controlled study. Br J Rheumatol 1989:28: 128-33
121. Willkens RF, Urowitz MB, Stablein DM, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992: 35: 849-56
122. Faarvang KL, Egsmose C, Kryger P, et al, Hydroxychloroquine and sulfasalazine alone and in combination in rheumatoid arthritis: a randomized double-blind trial. Ann Rheum Dis 1993: 52: 711-5
123. Haar D, Solvkjaer M, Unger B. et al. A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. Scand J Rheumatol 1993:22: 113-8
124. Tiliakos NA, Low-dose cytotoxic drug combination therapy in intractable rheumatoid arthritis: two years later. Arthritis Rheum 1986; 29 Suppl.: S79
125. Ferraz MB, Pinheiro CRC. Helfenstein M. et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis: a multi-center randomized placebo-controlled trial. Scand J Rheumatol 1994: 23: 231-6
126. Fries JF, Williams CA. Ramey D, et al. The relative toxicity of disease-modifying anti-rheumatic drugs. Arthritis Rheum 1993: 36: 297-306
127. Wolfe F, Hawley DJ, Kathey MA, Termination of slow-acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990: 17: 994-1002
128. Pincus TE, Marcum SB, Callahan LF, Long-term drug therapy tor rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992: 19: 1885-94
129. Wilke WS, Calabrese LH, Krall PL, et al, In: Rau R, editor. Low-dose methotrexate therapy in rheumatic disease. Vol. 9. Basel: Karger. 1986: 134-44
130. Fries JF, Singh G, Lenert L, et al. Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990:33: 1611-9
131. Landewe RBM, Miltenburg AMM, Breedveld FC, et al, Cyclosporin and chloroquine synergistically inhibit the Interferongamma production by CD4-positive and CD8-posilive synovial T-cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353-7
132. Dijkmans BAC, DeVries E, DeVreede TM. Synergistic and additive effects of disease-modifying anti-rheumatic drugs combined with chloroquine on the mitogen-driven stimulation of mononuclear cells. Clin Exp Rheumatol 1990: 8: 455-9
133. Brahn E, Peacock DJ, Banquerigo MS. Suppression of collagen-induced arthritis by combination of cyclosporin A and methotrexate therapy. Arthritis Rheum 1991; 34: 1282-8
134. Koopman WJ, The future of biologies in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1994; 23 Suppl. 6: 50-8
135. Elliott MJ, Maini RN, Feldmann M. et al. The treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-alpha. Arthritis Rheum 1993; 36: 1681-90
136. Elliott MJ, Maini RN, Feldmann M, et al. Randomized doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1995:344: 1105-10
137. Campion GV, The prospect for cytokine-based therapeutic strategies in rheumatoid arthritis. Ann Rheum Dis I994; 53: 485-7
138. Bell R, Wilke W. Tuggle C. et al. Treatment of rheumatoid arthritis with anti-CD5: possible synergy between biologic and traditional immunosuppressive therapy (abstract]. Arthritis Rheum 1992; 35 Suppl.: R30
139. Tilley B, Alarcon G. Heyse S, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995; 122 (2): 81-9
140. Kloppenburg M, Breedveld FC, Terwiel J, et al, Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37 (5): 629-36
141. Kloppenburg M, Breedveld FC, Dijkmans BAC. Minocycline in rheumatoid arthritis: rationale and trial results. Clin 1mmunother 1996:5 (I): 1-4